Phase I study and preclinical efficacy evaluation of the mTOR inhibitor sirolimus plus gemcitabine in patients with advanced solid tumours

被引：0
|
作者：
J Martin-Liberal
M Gil-Martín
M Sáinz-Jaspeado
N Gonzalo
R Rigo
H Colom
C Muñoz
O M Tirado
X García del Muro
机构：
[1] The Royal Marsden Hospital,Department of Immunology
[2] Institut Català d'Oncologia L'Hospitalet,undefined
[3] Genitourinary Tumors,undefined
[4] Sarcoma and Melanoma Unit,undefined
[5] Genetics and Pathology,undefined
[6] Rudbeck Laboratory,undefined
[7] Uppsala University,undefined
[8] Institut Català d'Oncologia L'Hospitalet,undefined
[9] Laboratori de Farmacocinètica,undefined
[10] Hospital de Bellvitge,undefined
[11] Àrea de Bioquímica i Biologia Molecular,undefined
[12] Universitat de Barcelona,undefined
[13] Facultat de Farmàcia,undefined
[14] Institut d'Investigació Biomèdica de Bellvitge (IDIBELL),undefined
[15] Laboratori d'Oncología Molecular,undefined
[16] Sarcoma Research Group,undefined
来源：
British Journal of Cancer | 2014年 / 111卷
关键词：
gemcitabine; sirolimus; rapamycin; mTOR; phase I;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：858 / 865
页数：7
相关论文
共 50 条
  • [1] Phase I study and preclinical efficacy evaluation of the mTOR inhibitor sirolimus plus gemcitabine in patients with advanced solid tumours
    Martin-Liberal, J.
    Gil-Martin, M.
    Sainz-Jaspeado, M.
    Gonzalo, N.
    Rigo, R.
    Colom, H.
    Munoz, C.
    Tirado, O. M.
    Garcia del Muro, X.
    [J]. BRITISH JOURNAL OF CANCER, 2014, 111 (05) : 858 - 865
  • [2] Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer
    Bendell, J.
    O'Reilly, E. M.
    Middleton, M. R.
    Chau, I.
    Hochster, H.
    Fielding, A.
    Burke, W.
    Burris, H., III
    [J]. ANNALS OF ONCOLOGY, 2015, 26 (04) : 804 - 811
  • [3] Phase I study of sirolimus plus gemcitabine in patients with advanced solid tumors: A Spanish Group for Research on Sarcomas (GEIS) study
    Martin Liberal, Juan
    Gil, Marta
    Jimenez, Laura
    Ochoa de Olza, Maria
    Munoz, Carmen
    Gonzalo, Nuria
    Rigo, Raul
    Colom, Helena
    Sainz Jaspeado, Miguel
    Tirado, Oscar M.
    Garcia del Muro, Xavier
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] Phase I study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancies.
    Park, Haeseong
    Garrido-Laguna, Ignacio
    Naing, Aung
    Fu, Siqing
    Falchook, Gerald Steven
    Piha-Paul, Sarina Anne
    Wheler, Jennifer J.
    Hong, David S.
    Subbiah, Vivek
    Tsimberidou, Apostolia Maria
    Kaseb, Ahmed Omar
    Oki, Yasuhiro
    Zinner, Ralph
    Patel, Shreyaskumar
    Bravo, Vivianne Marie Velez
    Fanale, Michelle A.
    Meric-Bernstam, Funda
    Kurzrock, Razelle
    Janku, Filip
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy
    Park, Haeseong
    Garrido-Laguna, Ignacio
    Naing, Aung
    Fu, Siqing
    Falchook, Gerald S.
    Piha-Paul, Sarina A.
    Wheler, Jennifer J.
    Hong, David S.
    Tsimberidou, Apostolia M.
    Subbiah, Vivek
    Zinner, Ralph G.
    Kaseb, Ahmed O.
    Patel, Shreyaskumar
    Fanale, Michelle A.
    Velez-Bravo, Vivianne M.
    Meric-Bernstam, Funda
    Kurzrock, Razelle
    Janku, Filip
    [J]. ONCOTARGET, 2016, 7 (41) : 67521 - 67531
  • [6] Phase I Study of Fixed Dose Gemcitabine Plus Epirubicin in Patients With Advanced Solid Malignancies
    Mahadevan, Daruka
    Dreisbach, Luke
    Kristedja, Timothy
    Williams, Debbie
    Obregon, Yrma
    Kurtin, Sandy
    Von Hoff, Daniel D.
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2009, 32 (06): : 607 - 611
  • [7] Phase I study of oral CP-4126, a gemcitabine analog, in patients with advanced solid tumours
    Stuurman, F. E.
    Voest, E. E.
    Awada, A.
    Schellens, J. H. M.
    Witteveen, P. O.
    Bergeland, T.
    Hals, P. A.
    Hendlisz, A.
    [J]. EJC SUPPLEMENTS, 2010, 8 (07): : 135 - 135
  • [8] Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors
    Yoshitaka Seki
    Noboru Yamamoto
    Yosuke Tamura
    Yasushi Goto
    Takashi Shibata
    Maki Tanioka
    Hajime Asahina
    Hiroshi Nokihara
    Yasuhide Yamada
    Takashi Shimamoto
    Kazuo Noguchi
    Tomohide Tamura
    [J]. Cancer Chemotherapy and Pharmacology, 2012, 69 : 1099 - 1105
  • [9] Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors
    Seki, Yoshitaka
    Yamamoto, Noboru
    Tamura, Yosuke
    Goto, Yasushi
    Shibata, Takashi
    Tanioka, Maki
    Asahina, Hajime
    Nokihara, Hiroshi
    Yamada, Yasuhide
    Shimamoto, Takashi
    Noguchi, Kazuo
    Tamura, Tomohide
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (04) : 1099 - 1105
  • [10] Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies
    Gray, Heidi J.
    Bell-McGuinn, Katherine
    Fleming, Gini F.
    Cristea, Mihaela
    Xiong, Hao
    Sullivan, Danielle
    Luo, Yan
    McKee, Mark D.
    Munasinghe, Wijith
    Martin, Lainie P.
    [J]. GYNECOLOGIC ONCOLOGY, 2018, 148 (03) : 507 - 514
12345